<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="37685">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02615938</url>
  </required_header>
  <id_info>
    <org_study_id>chILD-EU HCQ</org_study_id>
    <nct_id>NCT02615938</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquin (HCQ) in Pediatric Interstitial Lung Disease (ILD)</brief_title>
  <acronym>chILD-EU_HCQ</acronym>
  <official_title>Hydroxychloroquine in Pediatric ILD: START Randomized Controlled in Parallel-group, Then Switch Placebo to Active Drug, and STOP Randomized Controlled in Parallel-Group to Evaluate the Efficacy and Safety of Hydroxychloroquine (HCQ)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matthias Griese</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory Phase 2a, randomized, double-blind, placebo-controlled,
      parallel-group, multinational study investigating the initiation or withdrawal of
      hydroxychloroquine in subjects with chILD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an explorative, prospective, randomized, double-blind, placebo controlled
      investigation of hydroxychloroquine (HCQ) in pediatric ILD. The treatments are organized in
      START and STOP blocks, which can be initiated in sequence, as needed by the subjects. Each
      patient can participate in each block only once. In the START block subjects are randomized
      to parallel-groups, then the placebo group is switched to active drug. In the STOP block,
      subjects on HCQ are randomized into parallel-groups treated with placebo or HCQ to
      investigate the withdrawal of HCQ for assessment of its efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Oxygen Saturation</measure>
    <time_frame>Baseline - 28 days</time_frame>
    <description>Start HCQ block</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of O2-flow</measure>
    <time_frame>Baseline - 28 days</time_frame>
    <description>Start HCQ block</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Oxygenation index</measure>
    <time_frame>Baseline - 28 days</time_frame>
    <description>Start HCQ block</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Oxygen Saturation</measure>
    <time_frame>28 days - 56 days</time_frame>
    <description>Start HCQ block</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of O2-flow</measure>
    <time_frame>28 days - 56 days</time_frame>
    <description>Start HCQ block</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Oxygenation index</measure>
    <time_frame>28 days - 56 days</time_frame>
    <description>Start HCQ block</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Oxygen Saturation</measure>
    <time_frame>Baseline - 84 days</time_frame>
    <description>Stop HCQ block</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of O2-flow</measure>
    <time_frame>Baseline - 84 days</time_frame>
    <description>Stop HCQ block</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Oxygenation index</measure>
    <time_frame>Baseline - 84 days</time_frame>
    <description>Stop HCQ block</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Forced vital capacity</measure>
    <time_frame>Visit 2 - 28 days</time_frame>
    <description>Start HCQ block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Forced vital capacity</measure>
    <time_frame>Visit - 84 days</time_frame>
    <description>Stop HCQ block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with opthalmologic abnormalities</measure>
    <time_frame>Visit 2 - 28 days</time_frame>
    <description>Start HCQ block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lab values (GOT/GPT/Crea/BUN/CK/GGT/LDH/BB/DIFF/drug level /glucose)</measure>
    <time_frame>Visit 2 - 28 days</time_frame>
    <description>Start HCQ block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lab values (GOT/GPT/Crea/BUN/CK/GGT/LDH/BB/DIFF/drug level /glucose)</measure>
    <time_frame>Visit - 84 days</time_frame>
    <description>Stop HCQ block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of QoL (PedsQl™ generic and chILD specific module)</measure>
    <time_frame>Visit 2 - 28 days</time_frame>
    <description>Start HCQ block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of QoL (PedsQl™ generic and chILD specific module)</measure>
    <time_frame>Visit - 84 days</time_frame>
    <description>Stop HCQ block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Visit 2 - 28 days</time_frame>
    <description>Start HCQ block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Visit - 84 days</time_frame>
    <description>Stop HCQ block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Weight for height</measure>
    <time_frame>Visit 2 - 28 days</time_frame>
    <description>Start HCQ block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Weight for height</measure>
    <time_frame>Visit - 84 days</time_frame>
    <description>Stop HCQ block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative amounts of Steroid equivalents</measure>
    <time_frame>Visit 2 - 28 days</time_frame>
    <description>Start HCQ block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative amounts of Steroid equivalents</measure>
    <time_frame>Visit - 84 days</time_frame>
    <description>Stop HCQ block</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Interstitial Lung Disease</condition>
  <condition>Diffuse Parenchymal Lung Disease</condition>
  <condition>Children´s Interstitial Lung Disease</condition>
  <arm_group>
    <arm_group_label>Start HCQ block Verum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During trial: Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg bw/d, p.o., one daily dose in the evening for 7 days, then reduction to 6,5 mg/kg bw/d; the maximum daily dose is 400mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Start HCQ block Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>At the beginning of the trial: Placebo for 4 weeks then Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg bw/d, p.o., one daily dose in the evening for 7 days, then reduction to 6,5 mg/kg bw/d for 3 weeks; the maximum daily dose is 400mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stop HCQ block Verum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individual dose, usually Hydroxychloroquine Sulfate (HCQ, Quensyl) 6-10 mg/kg bw/d, p.o., one daily dose in the evening; the maximum daily dose is 400 mg. The dose, on which the patient is included into the trial, should be continued for 3 months. After therapy of 3 months the medication will be stopped. The patients will be followed up for additional 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stop HCQ block Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive Placebo for 3 months and will be followed up for additional 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine sulfate</intervention_name>
    <description>Apply drug to modify lysosomal pH</description>
    <arm_group_label>Start HCQ block Verum</arm_group_label>
    <arm_group_label>Stop HCQ block Verum</arm_group_label>
    <other_name>Quensyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Apply Placebo not to modify lysosomal pH</description>
    <arm_group_label>Start HCQ block Placebo</arm_group_label>
    <arm_group_label>Stop HCQ block Placebo</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients should be clinically stable during baseline (between Visit 1 and 2) for
             inclusion into the study

               1. To determine this, attending physicians can use SpO2 in room air for patients on
                  room air or on O2-supplement; the absolute difference on SpO2 is expected not to
                  be ≥ 5% between Visit 1 and 2. For patients on respiratory support, the summary
                  key parameters should not change ≥ 20% between Visit 1 and 2 and

               2. No major changes in other medications between Visit 1 and 2

          2. Mature newborn ≥ 37 weeks of gestation, age ≥ 3 wks or infants and children (till age
             18 y) or previously preterm (≤ 37 weeks of gestation) babies or children and adults
             of all ages if chILD genetically diagnosed (see inclusion criterion 3.)

          3. Diagnosis of chronic (≥ 3 wks of duration) diffuse parenchymal lung disease (DPLD =
             chILD), defined in at least one of the following ways:

               1. chILD genetically diagnosed Surfactant dysfunction disorders including patients
                  with disease causing mutations in SFTPC, SFTPB, ABCA3, TTF1 (Nkx2-1), further
                  extremely rare entities. In this case, also previously preterm (≤ 37 weeks of
                  gestation) babies or children and adults of all ages can be included into the
                  study.

               2. chILD histologically diagnosed Chronic pneumonitis of infancy (CPI) Desquamative
                  interstitial pneumonia (DIP) Lipoid pneumonitis Cholesterol pneumonia
                  Nonspecific interstitial pneumonia (NSIP) PAP after the exclusion of mutations
                  in GMCSF-Ra/b and GMCSF autoantibodies Microvasculopathy Cryptogenic Organizing
                  Pneumonia Diffuse Alveolar Damage and Acute Interstitial Pneumonia Acute
                  Fibrinous and Organizing Pneumonia Respiratory Bronchiolitis-Interstitial Lung
                  Disease Usual interstitial pneumonia (UIP) Sarcoidosis Follicular
                  bronchitis/bronchiolitis/Lymphocytic interstitial pneumonia (LIP) unless
                  associated with immunodeficiency Giant cell interstitial pneumonia (GIP) Storage
                  disease with primary pulmonary involvement (e.g. Niemann Pick) Pulmonary
                  interstitial glycogenosis (cellular interstitial pneumonitis, histiocytoid
                  pneumonia) Neuroendocrine cell hyperplasia of infancy (NEHI) Hermansky-Pudlak
                  Syndrome Hypersensitivity pneumonitis (if not suitable for Stop EAA study of the
                  chILD-consortium) Other histology diagnosing chILD

               3. chILD clinically diagnosed Unclear RDS in the mature newborn, after the
                  exclusion as far as possible of infectious, lung structural, vascular and all
                  other known causes of chILD; the presence of radiological evidence of chILD; and
                  the presence of either tachypnoea, dyspnoea or oxygen requirement, or need of
                  mechanical ventilation.

             Idiopathic pulmonary haemorrhage (haemosiderosis)

          4. Start block: no HCQ treatment in the last 12 weeks Stop block: stable HCQ treatment
             for at least the last 12 weeks

          5. Ability of subject or/and legal representatives to understand character and
             individual consequences of clinical trial.

          6. Signed and dated informed consent of the subject (if subject has the ability) and the
             representatives (of underaged children) must be available before start of any
             specific trial procedures.

        Exclusion criteria:

        chILD primarily related to developmental disorders chILD primarily related to growth
        abnormalities reflecting deficient alveolarisation chILD related to chronic aspiration
        chILD related to immunodeficiency chILD related to abnormalities in lung vessel structure
        chILD related to organ transplantation/organ rejection/GvHD chILD related to recurrent
        infections Acute severe infectious exacerbations Known hypersensitivity to HCQ, or other
        ingredients of the tablets (lactose-monohydrate, povidone, maize starch, magnesium
        stearate, hypromellose, macrogol or titanium dioxide (E 171), silicon dioxide or
        mannitol), to sucrose-octaacetate or sodium saccharine.

        Proven retinopathy or maculopathy Glucose-6-phosphate-dehydrogenase deficiency resulting
        in favism or hemolytic anemia Myasthenia gravis Hematopoetic disorders Pregnancy and
        lactation (Women with childbearing potential have to practice a medically accepted
        contraception during trial and till three months after the end of the treatment with HCQ,
        and a negative pregnancy test (serum or urine) should be existent before trial. Reliable
        contraception are systematic contraceptives (oral, implant, injection). Women that are
        sterile by surgery can participate in the trial).

        Participation in other clinical trials during the present clinical trial or not beyond the
        time of 4 half-lives of the medication used, at least one week.

        Hereditary galactose intolerance, lactase deficiency or glucose-galactose-malabsorption
        Renal insufficiency at screening, defined as glomerular filtration rate (GFR) &lt; 40
        mL/min/1.73 m2 in patients age 3 to 8 weeks &lt; 60 mL/min/1.73 m2 in patients ≥ 8 weeks of
        age (KDIGO guideline 2012, K/DOQI guideline 2002) Liver disease, gastrointestinal
        disorder, haematological disorder, epilepsy or other neurological disorder, psoriasis,
        porphyria at the discretion of the treating physician Simultaneous prescription of other
        potentially nephrotoxic or hepatotoxic medication at the discretion of the treating
        physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Griese, Prof., MD</last_name>
    <role>Study Director</role>
    <affiliation>Pediatric Pneumology, Ludwig-Maximilians-University Munich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Meike Hengst, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Pneumology, Ludwig-Maximilians University Munich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias Griese, Prof., MD</last_name>
    <phone>+49 (0) 89 4400</phone>
    <phone_ext>57871</phone_ext>
    <email>Matthias.griese@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meike Hengst, MD</last_name>
    <phone>+49 (0) 89 4400</phone>
    <phone_ext>57870</phone_ext>
    <email>Meike.hengst@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum der Universität München, Haunersches Kinderspital</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Griese, Prof., MD</last_name>
      <phone>+49 (0) 89 4400</phone>
      <phone_ext>57870</phone_ext>
      <email>matthias.griese@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Meike Hengst, MD</last_name>
      <phone>+49 (0) 89 4400</phone>
      <phone_ext>57870</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt, Pneumologie, Allergologie, Mukoviszidose</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Zielen, Prof., MD</last_name>
      <phone>+49 (0) 69 6301</phone>
      <phone_ext>83063</phone_ext>
      <email>stefan.zielen@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Martin Rosewich, MD</last_name>
      <phone>+49 (0) 69 6301</phone>
      <phone_ext>83063</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Justus-Liebig-Universität, Allgemeine Pädiatrie u. Neonatologie</name>
      <address>
        <city>Gießen</city>
        <state>Hessen</state>
        <zip>35385</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lutz Nährlich, MD</last_name>
      <phone>+49 (0) 641 9855</phone>
      <phone_ext>7620</phone_ext>
      <email>lutz.naehrlich@paediat.med.uni-giessen.de</email>
    </contact>
    <contact_backup>
      <last_name>Azadeh Bagheri-Hanson, MD</last_name>
      <phone>+49 (0) 641 9855</phone>
      <phone_ext>7620</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolaus Schwerk, MD</last_name>
      <phone>+49 (0) 511 5329</phone>
      <phone_ext>138</phone_ext>
      <email>schwerk.nicolaus@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Martin Wetzke, MD</last_name>
      <phone>+49 (0) 511 5329</phone>
      <phone_ext>138</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Essen, Pädiatrische Pneumologie</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florian Stehling, MD</last_name>
      <phone>+49 (0) 201 723</phone>
      <phone_ext>3350</phone_ext>
      <email>florian.stehling@uk-essen.de</email>
    </contact>
    <contact_backup>
      <last_name>Uwe Mellies, PD, MD</last_name>
      <phone>+49 (0) 201 723</phone>
      <phone_ext>3350</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinik u. Poliklinik für Kinder- u. Jugendmedizin der Universität Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Freerk Prenzel, MD</last_name>
      <phone>+49 (0) 341 9726</phone>
      <phone_ext>838</phone_ext>
      <email>freerk.prenzel@medizin.uni-leipzig.de</email>
    </contact>
    <contact_backup>
      <last_name>Julia Gebhardt, MD</last_name>
      <phone>+49 (0) 341 9726</phone>
      <phone_ext>838</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Charité Berlin, Klinik für Pädiatrie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Mehl, MD</last_name>
      <phone>+49 (0) 30 4505</phone>
      <phone_ext>66552</phone_ext>
      <email>anne.mehl@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Susanne G. Lau, Prof., MD</last_name>
      <phone>+49 (0) 30 4505</phone>
      <phone_ext>66552</phone_ext>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 19, 2017</lastchanged_date>
  <firstreceived_date>November 8, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Matthias Griese</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
